A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Clinical Trial Grant
Administered By
Neurology, Epilepsy and Sleep
Awarded By
Biogen, Inc.
Start Date
June 8, 2018
End Date
May 21, 2021
Administered By
Neurology, Epilepsy and Sleep
Awarded By
Biogen, Inc.
Start Date
June 8, 2018
End Date
May 21, 2021